Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters











Database
Language
Publication year range
1.
J Neurosci ; 33(13): 5834-42, 2013 Mar 27.
Article in English | MEDLINE | ID: mdl-23536095

ABSTRACT

Competition between adult males for limited resources such as food and receptive females is shaped by the male pattern of pituitary growth hormone (GH) secretion that determines body size and the production of urinary pheromones involved in male-to-male aggression. In the brain, dopamine (DA) provides incentive salience to stimuli that predict the availability of food and sexual partners. Although the importance of the GH axis and central DA neurotransmission in social dominance and fitness is clearly appreciated, the two systems have always been studied unconnectedly. Here we conducted a cell-specific genetic dissection study in conditional mutant mice that selectively lack DA D2 receptors (D2R) from pituitary lactotropes (lacDrd2KO) or neurons (neuroDrd2KO). Whereas lacDrd2KO mice developed a normal GH axis, neuroDrd2KO mice displayed fewer somatotropes; reduced hypothalamic Ghrh expression, pituitary GH content, and serum IGF-I levels; and exhibited reduced body size and weight. As a consequence of a GH axis deficit, neuroDrd2KO adult males excreted low levels of major urinary proteins and their urine failed to promote aggression and territorial behavior in control male challengers, in contrast to the urine taken from control adult males. These findings reveal that central D2Rs mediate a neuroendocrine-exocrine cascade that controls the maturation of the GH axis and downstream signals that are critical for fitness, social dominance, and competition between adult males.


Subject(s)
Body Size/physiology , Growth Hormone/metabolism , Pituitary Gland/metabolism , Prolactin/metabolism , Receptors, Dopamine D2/metabolism , Analysis of Variance , Animals , Benzamides/pharmacokinetics , Body Size/drug effects , Body Size/genetics , Body Weight/drug effects , Body Weight/genetics , Case-Control Studies , Catatonia/chemically induced , Catatonia/metabolism , Dopamine Antagonists/pharmacology , Eating/drug effects , Eating/genetics , Eating/physiology , Female , Haloperidol/pharmacology , Insulin-Like Growth Factor I/metabolism , Intermediate Filament Proteins/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nerve Tissue Proteins/genetics , Nestin , Oligodeoxyribonucleotides, Antisense/pharmacology , Pheromones/urine , Pituitary Gland/drug effects , Prolactin/genetics , Protein Binding/drug effects , Protein Binding/genetics , Proteins/metabolism , Radioimmunoassay , Receptors, Dopamine D2/deficiency , Receptors, Dopamine D2/genetics , Social Dominance , Territoriality , Tritium/pharmacokinetics
2.
Nat Neurosci ; 14(8): 1033-8, 2011 Jul 10.
Article in English | MEDLINE | ID: mdl-21743470

ABSTRACT

Dopamine (DA) D2 receptors expressed in DA neurons (D2 autoreceptors) exert a negative feedback regulation that reduces DA neuron firing, DA synthesis and DA release. As D2 receptors are mostly expressed in postsynaptic neurons, pharmacological and genetic approaches have been unable to definitively address the in vivo contribution of D2 autoreceptors to DA-mediated behaviors. We found that midbrain DA neurons from mice deficient in D2 autoreceptors (Drd2(loxP/loxP); Dat(+/IRES-cre), referred to as autoDrd2KO mice) lacked DA-mediated somatodendritic synaptic responses and inhibition of DA release. AutoDrd2KO mice displayed elevated DA synthesis and release, hyperlocomotion and supersensitivity to the psychomotor effects of cocaine. The mice also exhibited increased place preference for cocaine and enhanced motivation for food reward. Our results highlight the importance of D2 autoreceptors in the regulation of DA neurotransmission and demonstrate that D2 autoreceptors are important for normal motor function, food-seeking behavior, and sensitivity to the locomotor and rewarding properties of cocaine.


Subject(s)
Cocaine/administration & dosage , Dopamine Uptake Inhibitors/administration & dosage , Motivation/physiology , Receptors, Dopamine D2/deficiency , Reward , Analysis of Variance , Animals , Autoradiography , Baclofen/pharmacology , Choice Behavior/physiology , Conditioning, Operant , Dihydroxyphenylalanine/metabolism , Dopamine/metabolism , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Drug Interactions , Enzyme Inhibitors/pharmacology , Exploratory Behavior/physiology , Food , GABA-B Receptor Agonists/pharmacology , Hydrazines/pharmacology , Hyperkinesis/drug therapy , Hyperkinesis/physiopathology , In Vitro Techniques , Maze Learning/physiology , Membrane Potentials/drug effects , Membrane Potentials/genetics , Mesencephalon/cytology , Mice , Mice, Knockout , Motor Activity/genetics , Neurons/physiology , Quinpirole/pharmacology , Reinforcement Schedule , Sulpiride/pharmacology
3.
Am J Physiol Endocrinol Metab ; 293(5): E1341-51, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17848635

ABSTRACT

Dopamine D2 receptor (D2R) knockout (KO) female mice develop chronic hyperprolactinemia and pituitary hyperplasia. Our objective was to study the expression of the mitogen fibroblast growth factor (FGF2) and its receptor, FGFR1, comparatively in pituitaries from KO and wild-type (WT) female mice. We also evaluated FGF2 subcellular localization and FGF2 effects on pituitary function. FGF2-induced prolactin release showed a similar response pattern in both genotypes, even though basal and FGF2-stimulated release was higher in KO. FGF2 stimulated pituitary cellular proliferation (MTS assay and [(3)H]thymidine incorporation), with no differences between genotypes. FGF2 concentration (measured by ELISA) in whole pituitaries or cultured cells was lower in KO (P < 0.00001 and 0.00014). Immunofluorescence histochemistry showed less FGF2 in pituitaries from KO females and revealed a distinct FGF2 localization pattern between genotypes, being predominantly nuclear in KO and cytosolic in WT pituitaries. Finally, FGF2 could not be detected in the conditioned media from pituitary cultures of both genotypes. FGFR1 levels (Western blot and immunohistochemistry) were higher in pituitaries of KO. Basal concentration of phosphorylated ERKs was lower in KO cells (P = 0.018). However, when stimulated with FGF2, a significantly higher increment of ERK phosphorylation was evidenced in KO cells (P < or = 0.02). We conclude that disruption of the D2R caused an overall decrease in pituitary FGF2 levels, with an increased distribution in the nucleus, and increased FGFR1 levels. These results are important in the search for reliable prognostic indicators for patients with pituitary dopamine-resistant prolactinomas, which will make tumor-specific therapy possible.


Subject(s)
Fibroblast Growth Factor 2/metabolism , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Prolactinoma/metabolism , Receptors, Dopamine D2/deficiency , Animals , Blotting, Western , Cell Growth Processes/physiology , Enzyme-Linked Immunosorbent Assay , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Hyperplasia , Immunohistochemistry , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Confocal , Microscopy, Fluorescence , Phosphorylation , Pituitary Gland, Anterior/cytology , Prolactin/metabolism , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Receptors, Dopamine D2/metabolism
4.
Front Horm Res ; 35: 50-63, 2006.
Article in English | MEDLINE | ID: mdl-16809922

ABSTRACT

Dopamine receptor type 2 (D2R) knockout mice (KO) have chronic hyperprolactinemia, pituitary hyperplasia, and a moderate decrease in MSH content. They are also growth retarded evidencing an alteration in the GH-IGF-I axis. In D2R KO, lactotropes do not show dense secretory granules but degranulated cells and fewer somatotropes, gonadotropes and thyrotropes. Prolactin levels are always higher in female than in male knockouts, and in accordance, pituitary hyperplasia is observed at 8 months only in females. After 16 months of age, highly vascularized adenomas develop, especially in females. Prominent vascular channels in the hyperplastic and adenomatous pituitaries, as well as extravasated red blood cells not contained in capillaries is also a common finding. Prolactin is not the factor that enhances the hyperplastic phenotype in females while estrogen is a permissive factor. VEGF-A expression is increased in pituitaries from D2R KO. VEGF-A is expressed in follicle stellate cells. Because D2R receptors are found in lactotropes and not in follicle stellate cells, it may be inferred that a paracrine-derived factor from lactotropes is acting on follicle stellate cells to increase VEGF-A expression. VEGF-A does not induce pituitary cell proliferation, even though it enhances prolactin secretion. But it may act on adjacent endothelial cells and participate in the angiogenic process that increases the availability of different growth factors and mitogens. The D2R knockout mouse represents a unique animal model to study dopamine-resistant prolactinomas, and VEGF-A may be an alternative therapeutic target in this pathology.


Subject(s)
Disease Models, Animal , Mice, Knockout/genetics , Pituitary Neoplasms/genetics , Prolactinoma/genetics , Receptors, Dopamine D2/genetics , Animals , Cell Adhesion , Drug Resistance, Neoplasm , Female , Hyperplasia/etiology , Male , Mice , Neovascularization, Pathologic , Peliosis Hepatis/etiology , Pituitary Gland/pathology , Prolactinoma/blood supply , Prolactinoma/complications , Receptors, Dopamine D2/deficiency , Sex Characteristics , Vascular Endothelial Growth Factor A/physiology
5.
Endocrinology ; 146(7): 2952-62, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15817666

ABSTRACT

Vascular endothelial growth factor (VEGF)-A is an important angiogenic cytokine in cancer and pathological angiogenesis and has been related to the antiangiogenic activity of dopamine in endothelial cells. We investigated VEGF expression, localization, and function in pituitary hyperplasia of dopamine D2 receptor (D2R)-knockout female mice. Pituitaries from knockout mice showed increased protein and mRNA VEGF-A expression when compared with wild-type mice. In wild-type mice, prolonged treatment with the D2R antagonist, haloperidol, enhanced pituitary VEGF expression and prolactin release, suggesting that dopamine inhibits pituitary VEGF expression. VEGF expression was also increased in pituitary cells from knockout mice, even though these cells proliferated less in vitro when compared with wild-type cells, as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium proliferation assay, proliferating cell nuclear antigen expression, and [(3)H]thymidine incorporation. In contrast to other animal models, estrogen did not increase pituitary VEGF protein and mRNA expression and lowered serum prolactin secretion in vivo and in vitro in both genotypes. VEGF (10 and 30 ng/ml) did not modify pituitary cell proliferation in either genotype and increased prolactin secretion in vitro in estrogen-pretreated cells of both genotypes. But conditioned media from D2R(-/-) cells enhanced human umbilical vein cell proliferation, and this effect could be partially inhibited by an anti-VEGF antiserum. Finally, using dual-labeling immunofluorescence and confocal laser microscopy, we found that in the hyperplastic pituitaries, VEGF-A was mostly present in follicle-stellate cells. In conclusion, pituitary VEGF expression is under dopaminergic control, and even though VEGF does not promote pituitary cellular proliferation in vitro, it may be critical for pituitary angiogenesis through paracrine actions in the D2R knockout female mice.


Subject(s)
Haloperidol/analogs & derivatives , Pituitary Gland/metabolism , Receptors, Dopamine D2/deficiency , Vascular Endothelial Growth Factor A/metabolism , Animals , Cell Proliferation/drug effects , Cells, Cultured , Culture Media, Conditioned/chemistry , Dopamine Antagonists/pharmacology , Estrogens/pharmacology , Female , Haloperidol/pharmacology , Humans , Hyperplasia , Mice , Mice, Knockout , Pituitary Gland/pathology , Prolactin/blood , Prolactin/metabolism , RNA, Messenger/metabolism , Tissue Distribution , Umbilical Veins/cytology , Vascular Endothelial Growth Factor A/analysis , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/pharmacology
6.
J Neurosci ; 21(11): 3756-63, 2001 Jun 01.
Article in English | MEDLINE | ID: mdl-11356863

ABSTRACT

The dopamine D(4) receptor (D(4)R) is predominantly expressed in the frontal cortex (FC), a brain region that receives dense input from midbrain dopamine (DA) neurons and is associated with cognitive and emotional processes. However, the physiological significance of this dopamine receptor subtype has been difficult to explore because of the slow development of D(4)R agonists and antagonists the selectivity and efficacy of which have been rigorously demonstrated in vivo. We have attempted to overcome this limitation by taking a multidimensional approach to the characterization of mice completely deficient in this receptor subtype. Electrophysiological current and voltage-clamp recordings were performed in cortical pyramidal neurons from wild-type and D(4)R-deficient mice. The frequency of spontaneous synaptic activity and the frequency and duration of paroxysmal discharges induced by epileptogenic agents were increased in mutant mice. Enhanced synaptic activity was also observed in brain slices of wild-type mice incubated in the presence of the selective D(4)R antagonist PNU-101387G. Consistent with greater electrophysiological activity, nerve terminal glutamate density associated with asymmetrical synaptic contacts within layer VI of the motor cortex was reduced in mutant neurons. Taken together, these results suggest that the D(4)R can function as an inhibitory modulator of glutamate activity in the FC.


Subject(s)
Cerebral Cortex/physiopathology , Receptors, Dopamine D2/deficiency , Seizures/physiopathology , 4-Aminopyridine/pharmacology , Animals , Bicuculline/pharmacology , Cerebral Cortex/drug effects , Convulsants/pharmacology , Dopamine/metabolism , Dopamine D2 Receptor Antagonists , Dose-Response Relationship, Drug , Glutamic Acid/metabolism , Immunohistochemistry , In Vitro Techniques , Membrane Potentials/drug effects , Mice , Mice, Neurologic Mutants , Motor Cortex/drug effects , Motor Cortex/metabolism , Motor Cortex/physiopathology , Neural Inhibition/drug effects , Neural Inhibition/genetics , Patch-Clamp Techniques , Piperazines/pharmacology , Presynaptic Terminals/metabolism , Pyramidal Cells/drug effects , Pyramidal Cells/metabolism , Receptors, Dopamine D2/genetics , Receptors, Dopamine D4 , Seizures/chemically induced , Sulfonamides/pharmacology
7.
Cell ; 90(6): 991-1001, 1997 Sep 19.
Article in English | MEDLINE | ID: mdl-9323127

ABSTRACT

The human dopamine D4 receptor (D4R) has received considerable attention because of its high affinity for the atypical antipsychotic clozapine and the unusually polymorphic nature of its gene. To clarify the in vivo role of the D4R, we produced and analyzed mutant mice (D4R-/-) lacking this protein. Although less active in open field tests, D4R-/- mice outperformed wild-type mice on the rotarod and displayed locomotor supersensitivity to ethanol, cocaine, and methamphetamine. Biochemical analyses revealed that dopamine synthesis and its conversion to DOPAC were elevated in the dorsal striatum from D4R-/- mice. Based on these findings, we propose that the D4R modulates normal, coordinated and drug-stimulated motor behaviors as well as the activity of nigrostriatal dopamine neurons.


Subject(s)
Central Nervous System Depressants/pharmacology , Cocaine/pharmacology , Dopamine Agents/pharmacology , Ethanol/pharmacology , Methamphetamine/pharmacology , Narcotics/pharmacology , Receptors, Dopamine D2/genetics , 3,4-Dihydroxyphenylacetic Acid/metabolism , Amino Acid Sequence , Animals , Antipsychotic Agents/pharmacology , Behavior, Animal/drug effects , Clozapine/pharmacology , Corpus Striatum/anatomy & histology , Corpus Striatum/chemistry , Corpus Striatum/metabolism , Dopamine/metabolism , Genotype , Humans , Levodopa/analysis , Levodopa/pharmacokinetics , Locomotion/drug effects , Maternal Behavior/drug effects , Mice , Mice, Knockout , Molecular Sequence Data , Motor Activity/drug effects , Mutagenesis, Site-Directed/physiology , Nucleus Accumbens/chemistry , Nucleus Accumbens/metabolism , Receptors, Dopamine D2/deficiency , Receptors, Dopamine D4 , Sensitivity and Specificity , Substantia Nigra/anatomy & histology , Substantia Nigra/chemistry , Substantia Nigra/metabolism , Transcription, Genetic/genetics
SELECTION OF CITATIONS
SEARCH DETAIL